Skip to main content

Table 5 Linear regression: association of socio-demographic and clinical factors with the domains of quality of life among people living with HIV/AIDS in Felege-Hiwot Referral Hospital, Northwest, Ethiopia, (N = 391)

From: Major depressive disorder and its association with adherence to antiretroviral therapy and quality of life: cross-sectional survey of people living with HIV/AIDS in Northwest Ethiopia

Sociodemographic and clinical factors Physical
β (95%CI)
Psychological
β (95%CI)
Independence
β (95%CI)
Social
β (95%CI)
Environmental
β (95%CI)
Spiritual
β (95%CI)
Age 18–29 Reference Reference Reference Reference Reference Reference
30–39 −0.05 (− 0.22, 0.11) 0.07 (− 0.09, 0.23) − 0.01 (− 0.16, 0.15) 0.12 (− 0.03, 0.28) 0.18 (0.01, 0.37) 0.07 (− 0.07, 0.20)
40–49 − 0.10 (− 0.27, 0.08) 0.10 (− 0.07, 0.27) −0.03 (− 0.20, 0.14) 0.10 (0.07, 0.27) 0.26 (0.06, 0.46) 0.08 (− 0.06, 0.23)
50+ −0.11 (− 0.32, 0.09) 0.16 (− 0.05, 0.36) − 0.09 (− 0.30, 0.09) 0.14 (− 0.05, 0.33) 0.23 (0.02, 0.46) 0.11 (− 0.05, 0.28)
Marital status Married/relationship Reference Reference Reference Reference Reference Reference
Single −0.10 (− 0.27, 0.07) 0.01 (− 0.16, 0.17) − 0.09 (− 0.25, 0.07) −0.16 (− 0.32, 0.01) 0.18 (− 0.02, 0.37) − 0.09 (− 0.23, 0.05)
Divorced/ widowed 0.01 (− 0.10, 0.13) 0.07 (− 0.04, 0.18) 0.06 (− 0.05, 0.17) −0.08 (− 0.19, 0.03) 0.07 (− 0.07, 0.20) −0.05 (− 0.14, 0.05)
Educational status Illiterate Reference Reference Reference Reference Reference Reference
Primary education 0.20 (0.07, 0.33) 0.17 (0.04, 0.30) 0.22 (0.09, 0.35) 0.11 (− 0.01, 0.24) 0.12 (− 0.03, 0.28) 0.12 (0.01, 0.22)
Secondary education 0.21 (0.06, 0.35) 0.22 (0.07, 0.36) 0.21 (0.07, 0.35) 0.13 (−0.01, 0.27) 0.31 (0.14, 0.48) 0.13 (0.01, 0.25)
Tertiary education 0.27 (0.06, 0.48) 0.51 (0.30, 0.72) 0.35 (0.15, 0.56) 0.16 (−0.04, 0.37) 0.33 (0.10, 0.57) 0.23 (0.06, 0.41)
Employment status Public servant −0.08 (− 0.26, 0.09) −0.09 (− 0.26, 0.09) 0.01 (− 0.16, 0.18) −0.01 (− 0.17, 0.16) −0.04 (− 0.23, 0.16) −0.09 (− 0.23, 0.06)
Self employed −0.04 (− 0.16, 0.08) 0.17 (0.05, 0.29) 0.07 (− 0.04, 0.19) −0.11 (− 0.22, 0.01) −0.01 (− 0.14, 0.13) −0.07 (− 0.17, 0.02)
Unemployed Reference Reference Reference Reference Reference Reference
Perceived social support Low support Reference Reference Reference Reference Reference Reference
Moderate support 0.15 (−0.05, 0.34) 0.34 (0.15, 0.53) 0.23 (0.05, 0.42) 0.10 (− 0.08, 0.29) 0.11 (−0.13, 0.34) 0.19 (0.03, 0.35)
High support 0.25 (0.06, 0.44) 0.60 (0.42, 0.79) 0.37 (0.19, 0.56) 0.68 (0.50, 0.87) 0.45 (0.22, 0.68) 0.28 (0.13, 0.44)
ART regimen First-line 0.15 (0.04, 0.27) 0.19 (0.07, 0.30) 0.11 (0.01, 0.23) 0.10 (−0.01, 0.21) 0.08 (−0.05, 0.22) 0.08 (− 0.02, 0.17)
Second-line Reference Reference Reference Reference Reference Reference
Functional Disability No 0.39 (0.28, 0.49) 0.55 (0.44, 0.66) 0.35 (0.25, 0.45) 0.25 (0.15, 0.35) 0.10 (−0.02, 0.22) 0.17 (0.08, 0.26)
Yes Reference Reference Reference Reference Reference Reference
Current CD4 count (last 6 months) < 200 Reference Reference Reference Reference Reference Reference
200–349 −0.07 (−0.27, 0.12) 0.07 (−0.12, 0.26) − 0.03 (− 0.21, 0.16) 0.04 (− 0.14, 0.22) −0.08 (− 0.30, 0.15) 0.14 (− 0.02, 0.30)
350–499 0.03 (− 0.16, 0.21) 0.08 (− 0.10, 0.26) 0.07 (− 0.10, 0.25) 0.04 (− 0.14, 0.21) −0.03 (− 0.24, 0.18) 0.13 (− 0.02, 0.28)
> 500 0.01 (− 0.17, 0.17) 0.01 (− 0.15, 0.18) −0.04 (− 0.20, 0.12) 0.03 (− 0.13, 0.19) −0.05 (− 0.24, 0.15) 0.05 (− 0.09, 0.19)
ART treatment duration in years 1–5 Reference Reference Reference Reference Reference Reference
6–10 0.17 (0.03, 0.32) 0.12 (−0.02, 0.27) 0.13 (−0.01, 0.27) 0.05 (− 0.09, 0.19) 0.01 (− 0.15, 0.18) 0.17 (0.05, 0.29)
11+ 0.03 (−0.11, 0.18) 0.03 (−0.12, 0.17) − 0.05 (− 0.19, 0.09) −0.04 (− 0.09, 0.19) −0.14 (− 0.30, 0.03) 0.04 (− 0.08, 0.16)
  1. The results in this table were identified in multivariate linear regression. All variables associated with overall QoL at > 0.2 were controlled multivariate analyses with each domain of QoL. First-line regimen is the use of first choice antiviral drugs and a switch to second-line regimen is recommended when there is treatment failure with first-line treatments. ART antiretroviral therapy